Atossa Therapeutics (NASDAQ:ATOS) Stock Passes Below 200-Day Moving Average of $1.35

Shares of Atossa Therapeutics, Inc. (NASDAQ:ATOSGet Rating) passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.35 and traded as low as $1.02. Atossa Therapeutics shares last traded at $1.06, with a volume of 1,333,191 shares.

Separately, StockNews.com initiated coverage on Atossa Therapeutics in a research report on Thursday, March 31st. They set a “sell” rating for the company.

The firm has a market capitalization of $134.22 million, a PE ratio of -5.89 and a beta of 1.98. The company has a fifty day moving average price of $1.04 and a 200-day moving average price of $1.35.

Atossa Therapeutics (NASDAQ:ATOSGet Rating) last announced its quarterly earnings results on Monday, May 9th. The company reported ($0.04) earnings per share for the quarter.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. D. E. Shaw & Co. Inc. grew its position in Atossa Therapeutics by 362.9% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 4,147,809 shares of the company’s stock worth $6,637,000 after acquiring an additional 3,251,752 shares in the last quarter. State Street Corp boosted its holdings in shares of Atossa Therapeutics by 4.2% in the 1st quarter. State Street Corp now owns 2,233,010 shares of the company’s stock worth $2,791,000 after purchasing an additional 90,960 shares during the period. Geode Capital Management LLC increased its position in shares of Atossa Therapeutics by 7.1% during the 3rd quarter. Geode Capital Management LLC now owns 2,109,160 shares of the company’s stock valued at $6,875,000 after purchasing an additional 140,415 shares during the last quarter. Renaissance Technologies LLC raised its holdings in Atossa Therapeutics by 79.5% during the 1st quarter. Renaissance Technologies LLC now owns 2,100,492 shares of the company’s stock valued at $2,626,000 after buying an additional 930,152 shares during the period. Finally, Bank of New York Mellon Corp lifted its position in Atossa Therapeutics by 2.5% in the third quarter. Bank of New York Mellon Corp now owns 477,291 shares of the company’s stock worth $1,556,000 after buying an additional 11,719 shares during the last quarter. Hedge funds and other institutional investors own 38.23% of the company’s stock.

Atossa Therapeutics Company Profile (NASDAQ:ATOS)

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

Read More

Receive News & Ratings for Atossa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.